NCT06101173View on ClinicalTrials.gov

A Study to Evaluate the Safety and Immunogenicity of Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

January 15, 2024

Primary Completion Date

March 15, 2024

Study Completion Date

September 11, 2024

Conditions
Poliomyelitis
Interventions
BIOLOGICAL

Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) (VLP-Polio)

1 dose of VLP-Polio vaccine (0.5ml) on Visit 1

BIOLOGICAL

Inactivated poliomyelitis vaccine (IPOL)

1 dose of IPOL vaccine (0.5ml) on Visit 1

BIOLOGICAL

VLP-Polio

1 dose of VLP-Polio vaccine (0.5ml) on Visit 1

BIOLOGICAL

IPOL

1 dose of IPOL vaccine (0.5ml) on Visit 1

BIOLOGICAL

VLP-Polio

1 dose of VLP-Polio vaccine (0.5ml) on Visit 1

BIOLOGICAL

IPOL

1 dose of IPOL vaccine (0.5ml) on Visit 1

Trial Locations (2)

Unknown

Nucleus Network Pty Ltd, Geelong

Nucleus Network Pty Ltd, Melbourne

Sponsors
All Listed Sponsors
collaborator

Novotech (Australia) Pty Limited

INDUSTRY

lead

CanSino Biologics Inc.

INDUSTRY

NCT06101173 - A Study to Evaluate the Safety and Immunogenicity of Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) in Healthy Adults | Biotech Hunter | Biotech Hunter